Glenmark Files an Application to the USFDA for its Nasal Spray
May 22, 2018
Source: Ddu
846
The U.S Food and Drug Administration received a new drug application from Glenmark Pharmaceuticals for its nasal spray Ryaltris, which is used for the treatment of seasonal allergic rhinitis (SAR) for above the age of 12-years. Ryaltris is an investigational fixed-dose combination nasal spray for which Glenmark submitted an NDA new drug application to the USFDA
The company informed that Ryaltris (olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg), formerly GSP 301 Nasal Spray, has been conditionally accepted by the USFDA as the brand name.
In case the NDA accepts it, the Prescription Drug User Fee Act (PDUFA) target action date will be assigned.
Glenmark’s conducted seven clinical trials using more than 4,000 patients to test the efficacy of Ryaltris.
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- AZ’s Farxiga Gets FDA Priority Review For Heart Failure January 8, 2020
- Global Recall of CyPass Micro-Stent by Alcon September 3, 2018
- Breakthrough Device Designation Granted to Digital Intervention for Alzheimer’s August 27, 2018
- FDA Approved Eye Drop Oxervate to Treat Neurotrophic Keratitis August 27, 2018
- Experimental Ebola Treatments Approved by Congo as it Sees Flare-Up in Cases August 24, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
